Anita Shet1,2, Ujjwal Neogi3, N Kumarasamy4, Ayesha DeCosta2, Suresh Shastri5, Bharat Bhushan Rewari5. 1. Department of Pediatrics, St. John's Medical College Hospital, Bangalore, India. 2. Division of Global Health, Karolinska Institutet, Stockholm, Sweden. 3. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 4. YRG Center for AIDS Research and Education, Chennai, India. 5. National AIDS Control Organization, Department of AIDS Control, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Abstract
OBJECTIVE: Combination antiretroviral therapy (ART) has improved in efficacy, durability and tolerability. Virological efficacy studies in India are limited. We determined incidence and predictors of virological failure among patients initiating first-line ART and described virological resuppression after confirmed failure, with the goal of informing national policy. METHODS: Therapy-naïve patients initiated on first-line ART as per national guidelines were monitored every 3 months for adherence and virological response over 2 years. Genotyping on baseline samples was performed to assess primary drug resistance. Multivariate Cox regression analysis was used to assess predictors of virological failure. RESULTS: Virological failure rate among 599 eligible patients was 10.7 failures per 100 person-years. Cumulative failure incidence was 13.2% in the first year and 16.5% over 2 years. Patients initiated on tenofovir had a significantly lower rate of virological failure than those on stavudine or zidovudine (6.7 vs. 11.9 failures per 100 person-years, P = 0.013). Virological failure was independently associated with age <40 years, mean adherence <95%, non-tenofovir-containing regimens and presence of primary drug resistance. In a subset of 311 patients who were reassessed after treatment failure, 19% (11/58) patients resuppressed their viral load to <400 copies/ml after confirmed virological failure. CONCLUSIONS: Our results support the inclusion of tenofovir as first-line ART in resource-limited settings and a role for regular adherence counselling and virological monitoring for enhanced treatment success. Detection of early virological failure should provide an opportunity to augment adherence counselling and repeat viral load testing before therapy switch is considered.
OBJECTIVE: Combination antiretroviral therapy (ART) has improved in efficacy, durability and tolerability. Virological efficacy studies in India are limited. We determined incidence and predictors of virological failure among patients initiating first-line ART and described virological resuppression after confirmed failure, with the goal of informing national policy. METHODS: Therapy-naïve patients initiated on first-line ART as per national guidelines were monitored every 3 months for adherence and virological response over 2 years. Genotyping on baseline samples was performed to assess primary drug resistance. Multivariate Cox regression analysis was used to assess predictors of virological failure. RESULTS:Virological failure rate among 599 eligible patients was 10.7 failures per 100 person-years. Cumulative failure incidence was 13.2% in the first year and 16.5% over 2 years. Patients initiated on tenofovir had a significantly lower rate of virological failure than those on stavudine or zidovudine (6.7 vs. 11.9 failures per 100 person-years, P = 0.013). Virological failure was independently associated with age <40 years, mean adherence <95%, non-tenofovir-containing regimens and presence of primary drug resistance. In a subset of 311 patients who were reassessed after treatment failure, 19% (11/58) patients resuppressed their viral load to <400 copies/ml after confirmed virological failure. CONCLUSIONS: Our results support the inclusion of tenofovir as first-line ART in resource-limited settings and a role for regular adherence counselling and virological monitoring for enhanced treatment success. Detection of early virological failure should provide an opportunity to augment adherence counselling and repeat viral load testing before therapy switch is considered.
Authors: Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Intern Med Date: 2019-04-02 Impact factor: 25.391
Authors: Awachana Jiamsakul; Azar Kariminia; Keri N Althoff; Carina Cesar; Claudia P Cortes; Mary-Ann Davies; Viet Chau Do; Brian Eley; John Gill; Nagalingeswaran Kumarasamy; Daisy Maria Machado; Richard Moore; Hans Prozesky; Elizabeth Zaniewski; Matthew Law Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Victor Ssempijja; Martha Nason; Gertrude Nakigozi; Anthony Ndyanabo; Ron Gray; Maria Wawer; Larry W Chang; Erin Gabriel; Thomas C Quinn; David Serwadda; Steven J Reynolds Journal: Clin Infect Dis Date: 2020-08-14 Impact factor: 9.079
Authors: Silvia Bertagnolio; Rachel L Beanland; Michael R Jordan; Meg Doherty; Gottfried Hirnschall Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226
Authors: Santosh K Karade; Manisha V Ghate; Devidas N Chaturbhuj; Dileep B Kadam; Subramanian Shankar; Nitin Gaikwad; Shraddha Gurav; Rajneesh Joshi; Suvarna S Sane; Smita S Kulkarni; Swarali N Kurle; Ramesh S Paranjape; Bharat B Rewari; Raman R Gangakhedkar Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889
Authors: Kenneth A Freedberg; Nagalingeswaran Kumarasamy; Ethan D Borre; Eric L Ross; Kenneth H Mayer; Elena Losina; Soumya Swaminathan; Timothy P Flanigan; Rochelle P Walensky Journal: AIDS Res Hum Retroviruses Date: 2018-05-03 Impact factor: 1.723
Authors: Amy Zheng; Nagalingeswaran Kumarasamy; Mingshu Huang; A David Paltiel; Kenneth H Mayer; Bharat B Rewari; Rochelle P Walensky; Kenneth A Freedberg Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396